After officially releasing Zarxio in the U.S. market, Novartis has now launched another interesting feat that the loyal clients of the Swiss pharmaceutical company will surely love — Beautiful Medicine.
Novartis announced the launching of Beautiful Medicine on Wednesday via Facebook. The interactive exhibit highlights the role of nature in the history and development of medicine. Prior to its launch, the pharmaceutical giant teased with a simple yet artistic poster of Beautiful Medicine which has since been its Facebook page's cover photo. The company captioned the photo: "Over the next weeks, we go 'au naturel' to celebrate the launch of Beautiful Medicine."
Two hours later, the exhibit was launched with Novartis posting a quick informational clip, which was captioned: "Beautiful Medicine is a Novartis interactive exhibit highlighting nature's role in the history of medicine. For millions of years, nature has equipped plants and other living organisms with their very own survival kits. Scientists continue to borrow from nature to defend against one of our greatest enemy — disease."
Beautiful MedicinePosted by Novartis on Wednesday, September 2, 2015
On the exhibit's main webpage, an introduction on what Beautiful Medicine is all about greets visitors. The short introduction reads: "Welcome to Beautiful Medicine, an exhibition curated by Novartis. This journey through time showcases nature's exquisite complexity and the ways it has shaped culture and medicine. With the help of technology, nature continues to reveal its mysteries to the benefit of us all."
The launching of Beautiful Medicine comes just after the company released Zarxio in the U.S. market after it received the approval of a U.S. appeals court for its sale in the country despite an appeal to hamper its release as the drug was said to be a copycat of Amgen's Neupogen, Reuters has learned.
Zarxio is the first approved biosimilar drug by the U.S. Food and Drug Administration. After a comprehensive examination of the drug's analytical, nonclinical and clinical data, it was approved by the agency on March 6. Novartis also announced Sandoz One Source on Thursday; it is said to be a patient services center that provides information and resources assistance to patients, according to Nasdaq.
